- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07398066
DEXmédétomidine pour l'analgésie postopératoire et la prévention du délire après une NEUROchirurgie (Essai DEX-NEURO) (DEX-NEURO)
DEXmédétomidine pour l'analgésie postopératoire et la prévention du délire après une NEUROchirurgie : un essai randomisé contrôlé par placebo en double aveugle (essai DEX-NEURO)
Post-craniotomy pain is common and often undertreated. Inadequate analgesia can lead to patient discomfort and higher opioid consumption, which may result in respiratory depression, sedation risks and impaired neurological assessment in the early postoperative period. The incidence of post-operative delirium after intracranial surgery was 19%, ranging from 12 to 26% caused by variation in clinical features and delirium assessment methods1. It is associated with increased morbidity, longer length of hospital stay, and harm to self or staffs.
Dexmedetomidine (Precedex) is a highly selective α2-adrenergic agonist with the properties of analgesia, sedative, anxiolytic and neuroprotection without significant respiratory depression. Most of the trials administered a loading dose of 0.5-1.0 μg/kg intravenous dexmedetomidine over 10 minutes followed by infusion dose 0.2-0.7 μg/kg/hour. The use of intraoperative dexmedetomidine is believed to reduce the usage of postoperative opioids where frequent neurological assessment is often required in neurosurgical patients. Beyond the benefit of analgesia, perioperative dexmedetomidine has been studied for prevention of postoperative delirium. Randomized trials in mixed noncardiac surgical populations reported that low-dose perioperative dexmedetomidine may reduce the incidence of delirium. Dexmedetomidine produces dose-dependent bradycardia and hypotension, which should be carefully monitored to maintain the cerebral perfusion pressure in brain surgery. However, most trials and meta-analyses have focused on general surgical or cardiac cohorts; the evidence remains limited in neurosurgical (craniotomy) patients.
Although it showed promising benefits of analgesia and neuroprotection in non-neurosurgical patients, recent meta-analyses of intraoperative dexmedetomidine reported high degree of heterogeneity due to the inclusion of varied procedures (elective vs emergent craniotomy), dosing regimes (loading dose only versus loading dose + infusion versus infusion only) and varied primary endpoints (postoperative pain scores, cumulative opioid consumption or incidence of delirium). Therefore, this randomized, double-blind, placebo-controlled trial is designed to examine the use of intravenous dexmedetomidine in the reduction of postoperative pain score and delirium in neurosurgical patients. We hypothesised that intravenous dexmedetomidine reduces postoperative pain score and delirium with lower need of rescue analgesia and amount of morphine consumption in patients undergoing craniotomy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
There are several similar studies been conducted in the literature search. However, the majority of the studies focus on the intensive care unit patient or non-neurosurgery patients. It is believed that intravenous dexmedetomidine can reduce the postoperative pain score with lesser need for rescue analgesia and morphine consumption to facilitate postoperative neurological assessment.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ka Ting Dr Ng, MBChB
- Numéro de téléphone: +60379492411
- E-mail: katingng1@gmail.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- All adult (American Society of Anaesthesiologists (ASA 1-2) who >18 years old and <65 years old undergoing elective craniotomy
Exclusion Criteria:
- Patients who are ASA 3-5 or BMI <18/ >40 or allergic to dexmedetomidine will be excluded. Patients with high-grade heart block or uncontrolled bradyarrhythmia will also be excluded.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Intravenous dexmedetomidine
Intravenous dexmedetomidine loading dose 0.5mcg/kg followed by 0.5mcg/kg/hour |
intravenous dexmedetomidine loading dose 0.5mcg/kg followed by 0.5mcg/kg/hour
Autres noms:
|
|
Comparateur placebo: Intravenous normal saline
intravenous normal saline loading and infusion dose |
Intravenous normal saline loading and infusion dose of normal saline |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative pain score at recovery area
Délai: In the recovery area after pushing out from the operation theatre (Post-operative 1-hour, Day 1, Day 2)
|
Numerical Rating Scale (0 no pain-10 most pain) |
In the recovery area after pushing out from the operation theatre (Post-operative 1-hour, Day 1, Day 2)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Need of rescue analgesia
Délai: In the recovery area after pushing out from operation theatre (Post-operative 1-hour)
|
Need to receive additional analgesia (bolus of ketamine, fentanyl, morphine) in the recovery area |
In the recovery area after pushing out from operation theatre (Post-operative 1-hour)
|
|
Total usage of postoperative morphine use in the first 24-hour
Délai: In the first 24-hour after surgery in neurointensive care unit
|
The amount of morphine usage in milligram |
In the first 24-hour after surgery in neurointensive care unit
|
|
Postoperative nausea or vomiting
Délai: Within the first 24-hour in neurointensive care unit
|
Incidence of nausea or vomiting in the first 24-hour in neurointensive care unit |
Within the first 24-hour in neurointensive care unit
|
|
Incidence of delirium
Délai: Day-1 and Day-2 in neurointensive care unit
|
Assessed by CAM-ICU scoring test |
Day-1 and Day-2 in neurointensive care unit
|
|
Patient satisfaction scale of analgesia control
Délai: Day-1 in neurointensive care unit
|
Numerical rating scale (0 not satisfy - 10 very satisfy) |
Day-1 in neurointensive care unit
|
|
Adverse events of dexmedetomidine (hypotension and bradycardia).
Délai: During surgery when intravenous dexmedetomidine is started
|
systolic blood pressure < 90, heart rate <60 |
During surgery when intravenous dexmedetomidine is started
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet. 2016 Oct 15;388(10054):1893-1902. doi: 10.1016/S0140-6736(16)30580-3. Epub 2016 Aug 16.
- Li X, Yang J, Nie XL, Zhang Y, Li XY, Li LH, Wang DX, Ma D. Impact of dexmedetomidine on the incidence of delirium in elderly patients after cardiac surgery: A randomized controlled trial. PLoS One. 2017 Feb 9;12(2):e0170757. doi: 10.1371/journal.pone.0170757. eCollection 2017.
- Zhao LH, Shi ZH, Chen GQ, Yin NN, Chen H, Yuan Y, Cao W, Xu M, Hao JJ, Zhou JX. Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients With Delayed Extubation After Craniotomy: A Randomized Controlled Trial. J Neurosurg Anesthesiol. 2017 Apr;29(2):132-139. doi: 10.1097/ANA.0000000000000260.
- Bielka K, Kuchyn I, Babych V, Martycshenko K, Inozemtsev O. Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic small es, Cyrillicholecystectomy: a randomized controlled study. BMC Anesthesiol. 2018 Apr 20;18(1):44. doi: 10.1186/s12871-018-0508-6.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Manifestations neurologiques
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Les troubles mentaux
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Confusion
- Manifestations neurocomportementales
- Troubles neurocognitifs
- Tumeurs, tissu nerveux
- Tumeurs du système nerveux
- Tumeurs, tissu vasculaire
- Tumeurs méningées
- Tumeurs du système nerveux central
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- La douleur
- Délire
- Méningiome
- Tumeurs cérébrales
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Préparations pharmaceutiques
- Azoles
- Imidazoles
- Solutions cristalloïdes
- Solutions isotoniques
- Solutions
- Dexmédétomidine
- Solution saline
Autres numéros d'identification d'étude
- 16023
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .